Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
一项随机、开放标签的 II 期研究比较了安德卡利昔单抗联合纳武利尤单抗与单用纳武利尤单抗治疗晚期胃癌的疗效,并确定了与生存相关的生物标志物。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2021-003580
Shah, Manish A; Cunningham, David; Metges, Jean-Philippe; Van Cutsem, Eric; Wainberg, Zev; Elboudwarej, Emon; Lin, Kai-Wen; Turner, Scott; Zavodovskaya, Marianna; Inzunza, David; Liu, Jinfeng; Patterson, Scott D; Zhou, Jingzhu; He, Jing; Thai, Dung; Bhargava, Pankaj; Brachmann, Carrie Baker; Cantenacci, Daniel V T